Oxygen Therapy Market By Product Type (Oxygen Source Equipment, Oxygen Delivery Devices, Accessories), By Application (Chronic Obstructive Pulmonary Disease (COPD), Asthma, Obstructive Sleep Apnea, Pneumonia, Cystic Fibrosis, Acute Respiratory Distress Syndrome (ARDS), COVID-19 & Other Respiratory Infections, Others), By Age Group (Pediatric, Adult, Geriatric), By End User (Hospitals, Home Healthcare Settings, Ambulatory Care Centers, Specialty Respiratory Clinics, Emergency Medical Services (EMS), Others), By Region and Companies — Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026–2035

Market Overview

Global Oxygen Therapy Market size is expected to be worth around US$ 62.8 Billion by 2035 from US$ 33.2 Billion in 2025, growing at a CAGR of 6.6% during the forecast period from 2026 to 2035. In 2025, North America led the market, achieving over 37.6% share with a revenue of US$ 12.47 Billion.

Oxygen therapy is a vital part of both acute and chronic respiratory care worldwide. It is used for various conditions, including COVID-19, pneumonia, chronic obstructive pulmonary disease (COPD), and severe asthma. The global demand for medical oxygen and home oxygen devices has surged, particularly during recent respiratory outbreaks, and this trend continues to grow due to ageing populations and an increasing prevalence of chronic respiratory diseases.

According to public health authority data, pneumonia and lower respiratory infections are among the leading causes of death in older adults, which drives the demand for hospital oxygen and increases interest in home oxygen solutions.

In response, governments have prioritised the resilience of oxygen supply by making investments in on-site oxygen generation, bulk oxygen logistics, and regulated distribution of oxygen cylinders, all aimed at reducing shortages during crises.

Clinically, supplemental oxygen is recommended for patients with hypoxemia, and pulse oximetry is commonly used to assess the need for therapy. Health agencies report that hospital oxygen consumption can increase significantly during respiratory surges, and home oxygen prescriptions have risen year after year in many countries.

While the penetration of oxygen devices is highest in high-income settings, there are still access gaps in low- and middle-income regions. Manufacturers, healthcare providers, and policymakers are now focusing on developing portable concentrators, oxygen conservation devices, and improving supply chain resilience to expand safe access to oxygen therapy.

Key Takeaways

• Market Size: The Global Oxygen Therapy Market size was US$ 33.2 billion in 2025. The market is estimated to grow to US$ 62.8 billion by 2035.
• Market Share: The Compound Annual Growth Rate (CAGR) of the market from 2026 to 2035 will be 6.6%.
• Product Type: Oxygen Source Equipment has the largest market share, accounting for 58.7% of total sales.
• Application: Chronic Obstructive Pulmonary Disease (COPD) leads the segment, accounting for 41.5% of total revenue.
• Age Group: Geriatric dominates the segment, accounting for 49.8% of total revenue.
• End User: Hospitals dominate the segment, accounting for 44.5% of total revenue.
• Regional Analysis: In 2025, North America led the market, achieving over 37.6% share with a revenue of US$ 12.47 Billion.

Product Type Analysis

The Oxygen Therapy Market is segmented by product type into Oxygen Source Equipment, Oxygen Delivery Devices, and Accessories, reflecting the clinical workflow of oxygen generation, administration, and patient interface. In 2025, Oxygen Source Equipment dominates the market with a 58.7% share, valued at USD 33.2 billion, driven by strong demand for concentrators, liquid oxygen systems, and cylinders across hospitals and home care settings.

The segment benefits from rising long-term oxygen therapy adoption, technological advancements in portable concentrators, and healthcare system emphasis on reducing inpatient burden through home-based care. Oxygen Delivery Devices account for 30.4% of the market, supported by steady usage of nasal cannulas, masks, ventilators, and high-flow oxygen systems in acute and chronic respiratory management.

Growth in this segment is linked to expanding critical care capacity, increasing surgical volumes, and broader use in emergency and ambulatory care. Accessories, including humidifiers, tubing, regulators, and flow meters, represent the remaining 10.9% share.

While lower in value contribution, accessories generate consistent replacement-driven demand due to wear, infection control requirements, and recurring use across care settings. Together, product segmentation reflects a market anchored by infrastructure-intensive source equipment, complemented by delivery and consumable components essential for therapy continuity.

Application Analysis

In the Oxygen Therapy Market, Chronic Obstructive Pulmonary Disease (COPD) is the leading application, commanding a significant 41.5% market share in 2025. This dominance is a reflection of the high global prevalence of COPD and the ongoing need for prolonged or lifelong oxygen support. Patients with COPD often require continuous or nocturnal oxygen therapy, which drives consistent use in both hospital and home care settings.

Asthma accounts for 18.0% of the market, primarily due to the need for episodic oxygen during acute exacerbations, particularly in emergency and inpatient situations. Obstructive Sleep Apnea contributes 15.0% to the market, mainly through nighttime oxygen supplementation used in conjunction with positive airway pressure devices.

Pneumonia holds a 10.0% share, with demand stemming from acute care and post-hospital recovery periods. Cystic Fibrosis represents 7.0% of the market, reflecting the long-term oxygen needs of patients in advanced stages of the disease. Acute Respiratory Distress Syndrome (ARDS) accounts for 4.0% of the market, driven by usage in intensive care settings.

COVID-19 and other respiratory infections contribute 2.5%, while other indications make up the remaining 2.0%. This highlights the wide-ranging clinical reliance on oxygen therapy across acute, chronic, and critical care pathways.

Age Group Analysis

The Oxygen Therapy Market, when segmented by age group, is dominated by the geriatric population, which accounts for 49.8% of total market share in 2025. This leadership is attributed to the high prevalence of chronic respiratory conditions such as COPD, pneumonia, and age-related pulmonary decline among elderly patients.

Older adults are more likely to require long-term or continuous oxygen therapy, particularly in home healthcare and assisted living environments, driving sustained equipment utilisation and replacement demand.

The adult population represents a significant secondary segment, supported by the rising incidence of asthma, obstructive sleep apnea, occupational lung disorders, and post-surgical oxygen requirements. Adults also contribute meaningfully to ambulatory and home-based oxygen therapy adoption, aided by the availability of portable and wearable oxygen systems.

The pediatric segment holds a comparatively smaller share but remains clinically important, driven by neonatal respiratory distress, congenital lung disorders, and pediatric asthma management. While pediatric oxygen therapy usage is often shorter in duration, it requires specialised devices and monitoring, supporting niche product demand.

Overall, age-based segmentation highlights the market’s strong dependence on ageing demographics, while also reflecting sustained demand across adult and pediatric respiratory care needs.

End User Analysis

By end user, hospitals account for the largest share of the Oxygen Therapy Market at 44.5% in 2025, reflecting their central role in acute care, emergency response, surgical procedures, and intensive care management. High oxygen consumption in inpatient settings, coupled with critical care admissions for respiratory failure and pneumonia, sustains hospital dominance.

Home healthcare settings form the fastest-expanding segment, supported by the shift toward outpatient care, cost containment strategies, and rising adoption of long-term oxygen therapy for chronic conditions such as COPD.

Ambulatory care centres contribute steadily to market demand through short-term oxygen administration during minor procedures and recovery. Speciality respiratory clinics play a growing role in managing chronic respiratory diseases, sleep disorders, and pulmonary rehabilitation programs.

Emergency Medical Services (EMS) represent a critical niche segment, relying on portable oxygen systems for pre-hospital stabilisation and transport. Other end users, including long-term care facilities and rehabilitation centres, add incremental demand. Collectively, end-user segmentation reflects a gradual transition from hospital-centric oxygen delivery toward decentralised, home- and community-based care models.

Key Market Segments

By Product Type

• Oxygen Source Equipment
  • Oxygen Concentrators
    • Portable Oxygen Concentrators (POCs)
    • Stationary Oxygen Concentrators
  • Liquid Oxygen Systems
  • Compressed Oxygen Cylinders
• Oxygen Delivery Devices
  • Oxygen Masks
  • Nasal Cannulas
  • Venturi Masks
  • Non-Rebreather Masks
  • High-Flow Nasal Cannula (HFNC) Systems
  • Others
• Accessories
• • Humidifiers
  • Tubing & Connectors
  • Regulators
  • Flow Meters
  • Others

By Application

• Chronic Obstructive Pulmonary Disease (COPD)
• Asthma
• Obstructive Sleep Apnea
• Pneumonia
• Cystic Fibrosis
• Acute Respiratory Distress Syndrome (ARDS)
• COVID-19 & Other Respiratory Infections
• Others

By Age Group

• Pediatric
• Adult
• Geriatric

By End User

• Hospitals
• Home Healthcare Settings
• Ambulatory Care Centres
• Speciality Respiratory Clinics
• Emergency Medical Services (EMS)
• Others

Drivers

Hospital Oxygen Infrastructure Resilience Driving Integrated System Investments

Hospital oxygen system resilience spending is a major market driver because healthcare systems are increasingly investing in reliable oxygen infrastructure following past supply disruptions and equipment-maintenance challenges.

The focus has shifted from purchasing individual devices to building complete oxygen-delivery systems capable of supporting continuous clinical operations. This includes investments in PSA plants, cylinders, manifolds, backup oxygen systems, flowmeters, pulse oximeters, spare-parts inventories, and biomedical engineering support.

Strengthening workforce capability, equipment maintenance, and oxygen-system reliability has become a key healthcare priority. These integrated infrastructure projects typically involve larger and longer-term contracts than standalone equipment purchases. As a result, hospitals and public health systems are expanding procurement of comprehensive oxygen-service solutions that improve preparedness, operational resilience, and long-term oxygen availability.

Challenges

Financing and Affordability Gaps Limiting Access to Medical Oxygen

Financing and affordability gaps remain a major challenge because medical oxygen is often not funded as a complete service covering equipment, maintenance, monitoring, training, and patient access. More than 5 billion people still lack access to safe and affordable medical oxygen services, highlighting the scale of the unmet need.

Estimates indicate that around US$ 6.8 billion annually is required to close acute medical and surgical oxygen coverage gaps in low- and middle-income countries. In many healthcare systems, funding is available for equipment acquisition but not for maintenance, spare parts, pulse oximetry, or technical support.

Patients may also face out-of-pocket costs for oxygen refills and related services. These financing gaps contribute to delayed procurement, inconsistent service delivery, and operational challenges, limiting the expansion of reliable oxygen infrastructure despite strong clinical demand.

Restraints

Weak Oxygen Infrastructure Constraining Reliable Therapy Delivery

Weak oxygen infrastructure remains a major restraint because effective oxygen therapy depends on an integrated system of concentrators, cylinders, manifolds, piping networks, pulse oximetry, maintenance support, and trained personnel rather than a standalone device. Many healthcare facilities continue to face gaps in procurement planning, technical capacity, equipment maintenance, and system monitoring.

Challenges such as unreliable electricity, limited plant redundancy, shortages of biomedical engineering support, and weak distribution logistics can lead to intermittent oxygen availability and reduced service quality. These limitations lower the utilisation of installed oxygen assets and increase the effective cost of care delivery.

Infrastructure weaknesses also delay healthcare facility investments and discourage large-scale procurement programs. As a result, demand for oxygen equipment, maintenance services, and long-term supply contracts is constrained despite strong clinical need.

Opportunity

Infrastructure Monetisation Through Long-Term Oxygen Service Contracts

This is a strategic future opportunity because current oxygen sales in many institutional markets remain transaction-based, while the larger untapped white space is infrastructure monetization through long-duration oxygen availability contracts built around pressure swing adsorption plants, maintenance, training, monitoring, and uptime guarantees.

WHO states it supports member states through logistics, technical guidance, training, forecasting, and oxygen systems deployment, and post-pandemic infrastructure reviews show PSA plants have become central to resilient supply planning.

The commercial pivot is from selling equipment to selling oxygen-service continuity, where vendors own plant commissioning, spare parts, biomedical engineering training, and predictive maintenance, potentially reducing stockout risk while creating higher lifetime value per hospital than one-time capex sales.

In India, Africa, Gulf markets, and mixed public-private health systems, this model can materially enlarge addressable revenue by bundling concentrators, manifolds, compressors, alarms, and service-level agreements into one annuity-style contract rather than relying on fragmented purchases.

Regional Analysis

In 2025, North America dominated the oxygen therapy market, capturing over 37.6% of the market share with a revenue of USD 12.47 billion. The market shows significant regional variation, influenced by factors such as healthcare infrastructure maturity, disease burden, reimbursement frameworks, and homecare adoption.

North America leads globally due to a high prevalence of chronic respiratory diseases, widespread use of long-term oxygen therapy, and advanced home healthcare systems. Robust reimbursement coverage, the quick uptake of portable oxygen concentrators, and well-established emergency and critical care services further solidify this regional dominance.

Europe follows closely, benefiting from an ageing population, increasing incidence of Chronic Obstructive Pulmonary Disease (COPD), and government-supported respiratory care programs. Countries with universal healthcare systems exhibit stable demand across hospitals and home care settings, particularly in chronic and geriatric care.

The Asia-Pacific region is the fastest-growing market, driven by large patient populations, escalating air pollution, high smoking rates, and improving access to healthcare services. Increased hospital capacity, greater awareness of respiratory disorders, and the growing affordability of oxygen concentrators are accelerating adoption, especially in China, India, and Southeast Asia.

Latin America shows moderate growth, supported by improving healthcare infrastructure and better management of pneumonia, asthma, and post-acute respiratory conditions, although access disparities continue to exist.

In contrast, the Middle East and Africa market remains relatively small but is gradually expanding due to investments in hospital infrastructure, emergency care services, and respiratory support capabilities. Overall, these regional dynamics indicate a shift toward decentralised oxygen therapy delivery while maintaining steady hospital demand.

Key Regions and Countries

North America

• The US
• Canada

Europe

• Germany
• France
• The U.K.
• Italy
• Spain
• Russia & CIS
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• ASEAN
• Australia & New Zealand
• Rest of Asia Pacific

Middle East & Africa

• GCC
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Mexico
• Rest of Latin America

Key Player Analysis

Competitive advantage in the global oxygen therapy market is achieved through broad product portfolio coverage spanning oxygen source equipment, delivery devices, and accessories, established distribution relationships with hospitals and home healthcare providers, and continued investment in portable and lightweight oxygen concentrator technology addressing growing demand for mobile and home-based respiratory care.

Major strategic priorities for leading manufacturers include expansion of portable oxygen concentrator product lines, improving patient mobility and battery life, development of high-flow nasal cannula systems for acute respiratory care applications, and growing investment in home healthcare distribution channels supporting the structural shift toward decentralised respiratory disease management for the ageing geriatric patient population.

Strong hospital procurement relationships, combined with expanding home healthcare and ambulatory care center presence, represent a critical competitive differentiator for manufacturers serving the dominant COPD treatment segment globally.

Top Key Players

• Ventec Life Systems, Inc.
• Inogen, Inc.
• ICU Medical (Smiths Medical)
• ResMed
• HERSILL S.L.
• OMRON Healthcare
• GE Healthcare
• Fisher & Paykel Healthcare Limited
• Respironics (a subsidiary of Koninklijke Philips N.V.)
• Tecno-Gaz Industries
• Allied Healthcare Products, Inc.
• Teleflex Incorporated
• Chart Industries
• DeVilbiss Healthcare (a subsidiary of Drive Medical)
• Drägerwerk AG & Co. KGaA
• Linde
• Caire Medical (Acquired by Niterra Co., Ltd., formerly NGK SPARK PLUG CO., LTD.)
• Rhythm Healthcare
• Other Key Players

Recent Developments

• In February 2026, ResMed introduced an upgraded high-flow nasal cannula system with integrated humidification technology, targeting hospital and emergency medical services buyers managing acute respiratory distress and COVID-19-related respiratory care.
• In March 2026, Drägerwerk AG & Co. KGaA expanded its stationary oxygen concentrator and accessories portfolio with enhanced flow meter and regulator technology, targeting speciality respiratory clinics and hospital procurement across European markets.
• In April 2026, Fisher & Paykel Healthcare Limited secured a multi-year supply agreement with a leading Asian hospital network covering its oxygen delivery device and accessories portfolio, expanding its institutional presence across COPD and pneumonia respiratory care procedures in the region.

Report Scope